Toshiba targets MR body diffusion
Body diffusion is the next frontier for Toshiba MR, according to John Zimmer, vice president of marketing for Toshiba America Medical Systems. The biggest issue is motion-related artifact, he said, but the company is coming up with techniques and software changes to address the problem.
Body diffusion is the next frontier for Toshiba MR, according to John Zimmer, vice president of marketing for Toshiba America Medical Systems. The biggest issue is motion-related artifact, he said, but the company is coming up with techniques and software changes to address the problem.
"The long-term goal is to give PET/CT a run for its money," Zimmer said.
An MR add-on that allows body diffusion imaging will cost about $50,000. A PET/CT scanner can cost millions.
TAMS already has software that supports diffusion-weighted MR of the body, as do Siemens and Philips. The packages are available commercially and clinical work has produced encouraging results. Abdominal studies directed at identifying cancer deliver the best results if the acquisition can be performed in a breath-hold, Zimmer said. After that, motion artifact degrades the image.
The company is focusing in the near term on techniques that increase signal-to-noise and thereby reduce acquisition times. This could reduce or eliminate image distortion due to respiration. The bigger issue, however, is finding clinical test sites to validate MR body diffusion, Zimmer said. PET/CT will serve as the benchmark, he said.
"We will need the imaging community to spend the time to do the cross validation and testing," he said.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
